VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
26 sept. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
National Brain Tumor Society Statement on Passing of Sen. John McCain
27 août 2018 14h59 HE
|
National Brain Tumor Society
Boston, MA , Aug. 27, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society is profoundly saddened to learn of the senator’s passing, and our thoughts immediately go out to his family, friends,...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
17 avr. 2018 08h00 HE
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
Profiling Brain Cancers for More Targeted Treatments
22 déc. 2017 09h03 HE
|
The Jackson Laboratory
Farmington, Conn., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Roel Verhaak, Ph.D., is not beholden to the status quo. After all, his field, computational biology, didn’t exist, at least not formally, when he...
National Brain Tumor Society 2017 Scientific Summit Showcases Research & Treatment Development Opportunities in Neuro-Oncology Field
31 oct. 2017 15h29 HE
|
National Brain Tumor Society
BOSTON, MA--(Marketwired - October 31, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, recently hosted its annual...
National Brain Tumor Society Announces Multitude of New Discoveries to Enable Potential Future Brain Tumor Treatments
27 juin 2017 12h05 HE
|
National Brain Tumor Society
BOSTON, MA--(Marketwired - June 27, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, today, through its subsidiary Cure...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
03 juin 2016 16h02 HE
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...
Collaborations in Neurosurgery: MRI Interventions' ClearPoint System and Monteris Medical's NeuroBlate System Utilized Jointly to Enable Laser Ablation of Brain Tumor
23 juin 2014 08h00 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif. and MINNEAPOLIS, June 23, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) and Monteris Medical, Corp. jointly announced the utilization of their respective product...